Prado-Carrillo, O.; Arenas-RamÃrez, A.; Llaguno-Munive, M.; Jurado, R.; Pérez-Rojas, J.; Cervera-Ceballos, E.; Garcia-Lopez, P.
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. Int. J. Mol. Sci. 2022, 23, 7715.
https://doi.org/10.3390/ijms23147715
AMA Style
Prado-Carrillo O, Arenas-RamÃrez A, Llaguno-Munive M, Jurado R, Pérez-Rojas J, Cervera-Ceballos E, Garcia-Lopez P.
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. International Journal of Molecular Sciences. 2022; 23(14):7715.
https://doi.org/10.3390/ijms23147715
Chicago/Turabian Style
Prado-Carrillo, Omar, Abner Arenas-RamÃrez, Monserrat Llaguno-Munive, Rafael Jurado, Jazmin Pérez-Rojas, Eduardo Cervera-Ceballos, and Patricia Garcia-Lopez.
2022. "Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells" International Journal of Molecular Sciences 23, no. 14: 7715.
https://doi.org/10.3390/ijms23147715
APA Style
Prado-Carrillo, O., Arenas-RamÃrez, A., Llaguno-Munive, M., Jurado, R., Pérez-Rojas, J., Cervera-Ceballos, E., & Garcia-Lopez, P.
(2022). Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells. International Journal of Molecular Sciences, 23(14), 7715.
https://doi.org/10.3390/ijms23147715